REGEN-COV and COVID-19, update on the drug profile and FDA status: A mini-review and bibliometric study


COVID-19 is caused by coronavirus (SARS-CoV-2) is a worldwide health crisis. This severe acute respiratory syndrome was declared an outbreak after the first case was reported in Wuhan, the capital city of Hubei Province in China. On March 11th, 2020, the World Health Organization (WHO) declared it as a pandemic. The pharmaceutical treatment of COVID-19 has garnered significant critical attention due to the unavailability of medications to treat COVID-19. Recently, researchers have shown an increased interest in the monoclonal antibody drugs to treat COVID-19 especially REGEN-COV (casirivimab and imdevimab). This review aims to highlight the relation between the drug and COVID-19 and the recently updated information on the monoclonal antibody REGEN-COV from the U.S. Food and Drug Administration and other authorities. It is also designed to focus on the bibliometric data of REGEN-COV for the last three years (2020, 2021, and 2021) in PubMed and Google Scholar.


Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088–95. DOI:

Sidebottom DB, Gill D. Ronapreve for prophylaxis and treatment of COVID-19. BMJ 2021;374:n2136. DOI:

Hussain M, Jabeen N, Raza F, et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol 2020;92:1580-6. DOI:

Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. N Engl J Med 2021;384:238-51. DOI:

Mahase E. COVID-19: UK approves first monoclonal antibody treatment. BMJ 2021;374:n2083. DOI:

Ikemura N, Hoshino A, Hihuchi Y, et al. SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. medRxiv 2021. DOI:

Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs 2021;81:2047-55. DOI:

FDA. Emergency Use Authorization (EUA) for REGEN-COV Center for Drug Evaluation and Research (CDER) Memorandum. 2022. Available from:

FDA, U. Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant. 2022. Available from: